News Releases by Yankee Public Relations
Unity Bank Launches Partnership with NID Housing Counseling Agency and Donates $5,000 for Community Education Programs
February 9, 2021
Unity Bank recently donated $5,000 to the NID Housing Counseling Agency (NID-HCA), a U.S. Department of Housing and Urban Development (HUD) approved national network of housing counselors and community-development consultants with offices in Plainfield and Allentown, Pa. Unity is launching a partnership with the agency to supplement the bank’s Low-Moderate Income Mortgage Program.
Unity Bank Donates $22,500 to Nonprofit Organizations as Customer Tribute
February 3, 2021
Unity Bank recently donated $22,500 to nonprofit organizations throughout its service area, a special one time gift on behalf of the bank’s customers. Nine nonprofits representing the bank’s various service regions each received a $2,500 gift.
FDA Extends Shelf Life of Octapharma’s cutaquig® 16.5% for Adult PI Patients
January 5, 2021
Octapharma USA today announced the U.S. Food & Drug Administration (FDA) has extended the expiration date of 42 existing lots of cutaquig® [Immune globulin, Subcutaneous (Human)-hipp, 16.5% Solution] that are currently in the distribution chain. The FDA decision extends the shelf life of all future lots of cutaquig® from 24 to 36 months when stored at 2°C to 8°C (36°F to 46°F). The six-month shelf life of cutaquig® stored at room temperature up to +25 ºC (77ºF) remains unchanged.
Unity Bank Donates $34,200 to Food Pantries in NJ and Lehigh Valley
December 22, 2020
Unity Bank and its employees have donated a record total of $34,200 to 19 food pantries in New Jersey and Lehigh Valley, Pennsylvania. The funds were contributed by Unity Bank employees and matched by the bank as part of a special annual holiday community service project that was started more than 10 years ago.
Octapharma USA Presents Research on Congenital & Acquired Bleeding Disorders at ASH Annual Meeting
December 3, 2020
Octapharma USA will present multiple clinical research posters focused on the efficacy and safety of fibryga®, Fibrinogen (Human) Lyophilized Powder for Reconstitution, for Intravenous Use in the treatment of congenital and acquired bleeding disorders during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, a virtual medical congress to be held December 5 – 8.
Octapharma USA Presents Results of Investigational Use of Octagam® 10% for Severe COVID-19 Patients at ASH Annual Meeting
December 2, 2020
Clinical research presented by Octapharma USA at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition will highlight the investigational use of high-dose Octagam® 10% [Immune Globulin Intravenous (Human)] for the most severe COVID-19 patients.
National Hemophilia Foundation Revises Treatment Guidelines for Factor 1 Deficiency to Include Octapharma’s fibryga
October 7, 2020
The National Hemophilia Foundation (NHF) has revised its treatment recommendations for congenital fibrinogen (Factor 1) deficiency to include fibryga®, Fibrinogen (Human) Lyophilized Powder for Reconstitution, for Intravenous Use. Fibryga® is a highly purified, virus inactivated, human plasma-derived fibrinogen concentrate produced by Octapharma.
Octapharma USA Announces Medicare Part B Approval of cutaquig 16.5% for Adult PI Patients
September 15, 2020
Octapharma USA today announced the Centers for Medicare & Medicaid Services (CMS) has modified the External Infusion Pump Local Coverage Determination to include cutaquig® 16.5%, the company’s subcutaneous immunoglobulin (SCIg), for use with electric and mechanical pumps. The Medicare Part B coverage determination is effective September 6, 2020.
Intravenous Immunoglobulin Significantly Reduces Respiratory Morbidity in COVID-19 Study Supported by Octapharma
September 9, 2020
An investigator-initiated study (IIS) supported by Octapharma USA has reported that intravenous immunoglobulin (IVIg) significantly improved hypoxia and reduced hospital length of stay and progression to mechanical ventilation in patients with COVID-19 pneumonia.
Octapharma Launches Phase 3 Superiority Study for Pediatric Acute-onset Neuropsychiatric Syndrome
September 3, 2020
Octapharma has launched a phase 3, multicenter superiority study to compare the effectiveness of PANZYGA® (immune globulin intravenous, human - ifas) 10% Liquid Preparation versus placebo in patients with pediatric acute-onset neuropsychiatric syndrome (PANS).
Unity Bank Supports Elumis Foundation’s Effort to Bring Electricity to Impoverished Families in Africa
August 20, 2020
Unity Bank has donated $2,500 to the Elumis Foundation to help support the organization’s mission of providing families in impoverished areas of the world with solar kits. The foundation was founded by Franklin Lakes teenagers Eva and Michael Sakellakis who were inspired by their father’s solar energy business.
Unity Bank’s 14th Annual Classic Car Show Benefitting Family Promise Will Be Virtual in 2020
June 9, 2020
Unity Bank is seeking sponsors and classic car owners for the 14th Annual Cruisin’ Bob’s Classic Car Show, which for the last 13 years has been held at the bank’s Clinton headquarters, but will be virtual this year due to the coronavirus pandemic. All proceeds from the car show will benefit Family Promise of Hunterdon County and Family Promise of Warren County.
Octapharma USA Extends Funding for COVID-19 Study Following Positive Preliminary Research Data
June 3, 2020
Following positive preliminary data, Octapharma USA is extending funding for an investigator-initiated study (IIS) focused on treating the most critical patients at the heart of the coronavirus pandemic, those experiencing hypoxia and who are at the highest risk of requiring mechanical ventilation.
Octapharma USA & BioMatrix Support Research Focused on COVID-19 & Myocardial Dysfunction
May 28, 2020
Octapharma USA and BioMatrix Specialty Pharmacy are supporting a new investigator-initiated research study led by Kelly McCants, M.D., Medical Director of the Norton Heart & Vascular Institute in Louisville, Ky., focused on treating patients with the coronavirus (COVID-19) and presenting with COVID-19-associated myocardial dysfunction.
FDA Approves Octapharma USA Investigational New Drug Application for Severe COVID-19 Patients
May 20, 2020
The U.S. Food and Drug Administration (FDA) has approved the investigational new drug (IND) application submitted by Octapharma USA for a phase three clinical trial on the efficacy and safety of Octagam® 10% [Immune Globulin Intravenous (Human)] therapy in COVID-19 patients with severe disease progression.
Unity Bank is Top Ranked New Jersey Community Bank on American Banker Magazine’s Top 200 List
May 14, 2020
Unity Bancorp, Inc. (NASDAQ: UNTY), the parent company of Unity Bank, was the top ranked New Jersey community bank on the recently published American Banker magazine list of the Top 200 Publicly Traded Community Banks with less than $2 billion in assets. Unity was ranked 15th nationally on the respected industry list, which reviewed 511 institutions throughout the U.S.
Unity Bank Provides $130 Million in PPP Loans, Saving Thousands of Jobs Through SBA COVID-19 Lending Program
April 29, 2020
Gary Shiman, Co-Owner and Executive Vice President of Bellari Home Remodeling of Branchburg, represents one of the nearly 1,000 businesses that will receive more than $130 million in Unity Bank loans through the Small Business Administration (SBA) Paycheck Protection Program (PPP), the special funding initiative designed to help small businesses survive the coronavirus (COVID-19) pandemic.
New COVID-19 Clinical Trial Supported by Octapharma USA
April 16, 2020
Octapharma USA is supporting a new investigator initiated clinical trial led by George Sakoulas, M.D. of Sharp Memorial Hospital in San Diego, California focused on treating the most critical patients at the heart of the coronavirus pandemic, those experiencing respiratory failure who become ventilator dependent.
Unity Bank Offering SBA Loans for Businesses Coping with COVID-19
April 2, 2020
In response to the coronavirus (COVID-19) pandemic, Unity Bank will be offering its customers the Small Business Administration (SBA) Paycheck Protection Program, a loan designed to provide a direct incentive for small businesses to keep their workers on the payroll.
Unity Bank is the Only NJ Bank to be Named One of the 2020 Best Places to Work in New Jersey
March 13, 2020
Unity Bank has been named one of the 2020 Best Places to Work in New Jersey – the only bank in New Jersey to make the prestigious list. It is the fourth year in a row that Unity has been honored by the survey and awards program.
As Global Coronavirus Concerns Grow, Octaplas™ Provides Enhanced Safety Option
February 6, 2020
“ Octaplas™, Pooled Plasma (Human), Solvent/Detergent (S/D) Treated Solution for Intravenous Infusion, provides that peace of mind the healthcare community is looking for,” said Octapharma USA President Flemming Nielsen. Read the full article on the Associated Press website.